takeda pharmaceutical co

Takeda And Noile-Immune Biotech Enter CAR-T Collaboration

Takeda and Noile-Immune Biotech collaborate to advance next generation CAR-T therapy effective for solid tumors.

Takeda Invests US$125 Million In Maverick’s T-Cell Platform

Maverick Therapeutics Inc. and Takeda will collaborate to develop a biologics platform for T-cell immunotherapy over the next five years.

Takeda & PvP Biologics To Develop Drugs Against Celiac Disease

Takeda Pharmaceuticals and PvP Biologics have signed an agreement to develop therapeutics targeting celiac disease.

What You Need To Know About Takeda’s Dengue Vaccine

Derek Wallace, global dengue program medical director of Takeda Pharmaceutical Company, on the company's plans for dengue and Zika vaccines.

Takeda Signs Cancer Therapeutics Collaboration With Crescendo Biologics

The collaboration will focus on discovery, development and commercialization of Humabodies®, a novel class of protein therapeutics.

Takeda To Develop Zika Vaccine With $19.8m BARDA Funding

The US$19.8 million initial funding will cover the development of a Zika vaccine through to a Phase I clinical trial.

Takeda, TiGenix Announce Phase III Trial Results For Crohn’s Disease Drug

A significantly greater proportion of patients in the treatment group versus the placebo group achieved combined remission at week 24.

Takeda, Altos Therapeutics To Develop Gastroparesis Treatment

The partnership will develop Altos’s proprietary compound ATC-1906 to address the symptoms of nausea and vomiting in gastroparesis patients.

Takeda Receives US$38 Million Polio Eradication Grant From Gates Foundation

With this funding, Takeda will develop, license and supply at least 50 million doses of a polio vaccine per year to more than 70 developing countries.

From Industry To Non-Profit And Back

Tachi Yamada, chief medical & scientific officer of Takeda Pharmaceuticals, shares his journey from academia to industry, non-profit organizations and back, and why Asia is now the place to be.